Physician profile
Fernando Hool
NPI 1770750788
$1,198.41
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $68.76 · 2023: $175 · 2024: $275 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.72 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $199.99 | 2021-2022 | |
| Novo Nordisk INC | $156.95 | 2021-2025 | Wegovy |
| Glaxosmithkline, LLC. | $135.07 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $120.02 | 2021-2025 | Gardasil 9, Proquad, Vaxelis |
| Exact Sciences Corporation | $67.09 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $49.31 | 2025 | Talicia |
| Dexcom, INC. | $35.61 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $30.90 | 2023 | |
| Neurocrine Biosciences, INC. | $29.16 | 2021 | |
| Aspira Women'S Health INC | $26.15 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.40 | 2024 | Fanapt, Hetlioz |
| Phadia US INC. | $20.06 | 2023 | Immunocap |
| Pfizer INC. | $17.10 | 2023 | |
| Evofem Biosciences, INC. | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Hool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.